MSI: MSI Methylation Sciences Inc. (MSI) Announces Results From the Horizon Phase 2 Trial for its Novel Treatment, MSI-195, for Major Depressive Disorder (MDD)

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 01/27/16 -- MSI Methylation Sciences Inc., a pharmaceutical company developing oral, small molecule therapies for major depressive disorder (MDD), a...